Synmosa Biopharma (4114) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Synmosa Biopharma (4114) has a cash flow conversion efficiency ratio of 0.018x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$185.72 Million ≈ $5.85 Million USD) by net assets (NT$10.10 Billion ≈ $318.18 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Synmosa Biopharma balance sheet independence to measure how much of total assets are equity-financed.
Synmosa Biopharma - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Synmosa Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Synmosa Biopharma earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Synmosa Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Synmosa Biopharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Harson Trading China Co Ltd
SHG:603958
|
0.049x |
|
Sanlux Co Ltd
SHE:002224
|
-0.001x |
|
Village Super Market Inc
NASDAQ:VLGEA
|
0.000x |
|
Sable Offshore Corp.
NYSE:SOC
|
-0.318x |
|
Servcorp Ltd
AU:SRV
|
0.361x |
|
Surya Semesta Internusa Tbk
JK:SSIA
|
0.001x |
|
Tibet Aim Pharm Inc
SHE:002826
|
0.104x |
|
Optotech Corp
TW:2340
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Synmosa Biopharma (2015–2025)
The table below shows the annual cash flow conversion efficiency of Synmosa Biopharma from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Synmosa Biopharma (4114) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$10.10 Billion ≈ $318.18 Million |
NT$411.57 Million ≈ $12.97 Million |
0.041x | -56.15% |
| 2024-12-31 | NT$8.40 Billion ≈ $264.61 Million |
NT$780.62 Million ≈ $24.59 Million |
0.093x | +47.08% |
| 2023-12-31 | NT$8.10 Billion ≈ $255.22 Million |
NT$511.93 Million ≈ $16.13 Million |
0.063x | -33.33% |
| 2022-12-31 | NT$6.65 Billion ≈ $209.47 Million |
NT$630.25 Million ≈ $19.86 Million |
0.095x | +30.05% |
| 2021-12-31 | NT$6.10 Billion ≈ $192.04 Million |
NT$444.29 Million ≈ $14.00 Million |
0.073x | +70.61% |
| 2020-12-31 | NT$5.95 Billion ≈ $187.60 Million |
NT$254.40 Million ≈ $8.02 Million |
0.043x | +558.15% |
| 2019-12-31 | NT$4.81 Billion ≈ $151.63 Million |
NT$-44.88 Million ≈ $-1.41 Million |
-0.009x | -361.48% |
| 2018-12-31 | NT$4.49 Billion ≈ $141.31 Million |
NT$16.00 Million ≈ $503.96K |
0.004x | +372.28% |
| 2017-12-31 | NT$3.97 Billion ≈ $124.93 Million |
NT$-5.19 Million ≈ $-163.64K |
-0.001x | -102.41% |
| 2016-12-31 | NT$4.35 Billion ≈ $137.14 Million |
NT$236.48 Million ≈ $7.45 Million |
0.054x | +593.84% |
| 2015-12-31 | NT$3.01 Billion ≈ $94.96 Million |
NT$23.60 Million ≈ $743.59K |
0.008x | -- |
About Synmosa Biopharma
Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, gr… Read more